Dostarlimab or pembrolizumab plus chemotherapy in previously untreated metastatic non-squamous non-small cell lung cancer: the randomized PERLA phase II trial Several PD-(L)1 inhibitors have been approved or are in development for the treatment of NSCLC, showing promising efficacy and tolerable safe...
Immunotherapy for Cancer Treatment Cancer is a leading cause of death worldwide, with millions of people dying from the disease each year. Although there are various treatment options available, the effectiveness of these treatments is often limited, and they can come with significant side effects....
targeted drugstoxicitiesTreatment of cancer has shifted dramatically over the past 2 decades. Targeted agents are used to block pathways known to drive tumor growth. Immunotherapy agents work by reversing cancer's ability to evade immune checkpoints, resulting in effective immune responses. With these...
As a result, the reprogrammed T-cells, or CAR T-cells, make protein that find and attach to antigens on cancer cells to help destroy the cancer cells. CAR-T-cells appear promising for the treatment of B-cell acute lymphoblastic leukemia (ALL) and other hematologic malignancies. Scroll to ...
The advent of immunotherapy has made an indelible mark on the field of cancer therapy, especially the application of immune checkpoint inhibitors in clinical practice. Although immunotherapy has proven its efficacy and safety in some tumors, many patient
" Dr. Curiel said. "We've shown that if you test all your immune therapy just in young mice and young people, you'll never learn how it works in older patients — the ones most at risk for cancer. You might conclude that drugs don't work in aged hosts, when they do. But they ...
Increasing evidence shows that PD-L1 protein undergoes degradation in proteasomes or lysosomes by multiple pathways, leading to enhanced immunotherapy for cancer. Although some specific drugs induce PD-L1 degradation and increase antitumor activity, the combination of these drugs with PD-L1/PD-1 ...
Scientists continue to research immunotherapies for lung cancer, including checkpoint inhibitors, therapeutic vaccines, and adoptive cell therapy. They’re also looking to see if combinations of these drugs will help. The following immunotherapy drugs have been approved for use in advanced non-small-cel...
Engineered T-cell receptor (TCR) therapy.This treatment removes T cells from your blood and reprograms them in a lab so they can find the cancer more easily. The engineered T cells look for tiny targets on the surface of your cancer cells. ...
In 2018, the first chemotherapy combination with ICI was approved by the FDA; carboplatin, pemetrexed, and pembrolizumab are now routinely used as a first-line therapy for non-small cell lung cancer. Similarly, the combination of nab-paclitaxel and atezolizumab (anti-PD-L1) was recently approved...